Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren PK and Safety in Pediatric Hypertension
NCT00834041Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of aliskiren in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoints: Maximum Plasma Concentration at Day 8, Area Under the Plasma Concentration-time Curve at Day 8 and 1 more. Started Apr 2009; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00834041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00834041.